Publications
PBPK/PBDE (50 POSTS)
2024 (2 POSTS)
PBPK modeling demonstrates that exposure time adjustment is unnecessary for setting an acute manganese inhalation exposure guideline
Perry CS, Verwiel AH, Covington TR, Proctor DM. 2024. PBPK modeling demonstrates that exposure time adjustment is unnecessary for setting an acute manganese inhalation exposure guideline. Regul Toxicol Pharmacol 153(Nov):105698; doi: 10.1016/j.yrtph.2024.105698. PMID: 39251127.
View AbstractProbabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese
Mittal L, Perry CS, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Anal. 44(9):2169-2186. doi: 10.1111/risa.14309. PMID: 38622492.
View Abstract2023 (1 POST)
Complex mixtures: Array PBPK modeling of jet fuel components
Sterner TR, Covington TR, Mattie DR. 2023. Complex mixtures: Array PBPK modeling of jet fuel components. Toxics 11(2):187; doi: 10.3390/toxics11020187. PMID: 36851061.
View Abstract2022 (1 POST)
Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population
Pouillot R, Farakos SS, Spungen J, Schaefer HR, Flannery BM, Van Doren JM. 2022. Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population. Toxicol Lett 367(Aug):67-75; doi: 10.1016/j.toxlet.2022.07.812. PMID: 35901988. Corrigendum: Toxicol Lett 2023 377(March):14-15; doi: 10.1016/j.toxlet.2023.01.011.
View Abstract2019 (1 POST)
Assessing children’s exposure to manganese in drinking water using a PBPK model
Yoon M, Ring C, Van Landingham CB, Suh M, Song G, Antonijevic T, Gentry PR, Taylor MD, Keen AM, Andersen ME, Clewell JH. 2019. Assessing children’s exposure to manganese in drinking water using a PBPK model. Toxicol Appl Pharmacol 380(Oct 1):114695; doi: 10.1016/j.taap.2019.114695.
View Abstract2017 (2 POSTS)
Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations
Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.
View AbstractEstimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis
Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.
2016 (1 POST)
Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling
Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.
View Abstract2015 (1 POST)
Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity
Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.
View Abstract2014 (1 POST)
Variation analysis of PBPK model parameters for describing the delivery of Cr(VI) to the small intestines of humans
Kirman CR, Proctor D, Suh M, Thompson CM, Harris MA, Haws LC, Hays SM. Variation analysis of PBPK model parameters for describing the delivery of Cr(VI) to the small intestines of humans. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.
View Abstract2013 (3 POSTS)
Physiologically based pharmacokinetic model for humans orally exposed to chromium
Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.
View AbstractUsing PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans
Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.
View AbstractHuman lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model
Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.
2012 (1 POST)
A calibrated human PBPK model for benzene inhalation with urinary bladder and bone marrow compartments
Knutsen JS, Kerger BD, Finley BL, Paustenbach DJ. 2012. A calibrated human PBPK model for benzene inhalation with urinary bladder and bone marrow compartments. Risk Anal 33 (7):1237–1251; doi: 10.1111/j.1539-6924.2012.01927.x. PMID: 23278103.
View Abstract2011 (1 POST)
Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX
Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
2010 (3 POSTS)
Physiological parameters and databases for PBPK modeling
Johns DO, Owens EO, Thompson CM, Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.
View AbstractExploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX
Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.
PBDEs in Newark Bay sediments
Staskal-Wikoff D, Burkhalter B, Stapleton H, Harris M. PBDEs in Newark Bay sediments. Presented at Dioxin 2010, San Antonio, TX, September 2010.
2009 (2 POSTS)
Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly
Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.
View AbstractScreening-level assessment of risk associated with exposure to PBDEs in vehicles
Staskal DF, Birnbaum LS. Screening-level assessment of risk associated with exposure to PBDEs in vehicles. Society for Toxicology 48th Annual Meeting, Baltimore, MD, March 2009.